



July 17, 2025

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai - 400 051

**BSE Limited**

P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
Mumbai - 400 001

**Symbol: LUPIN**

**Scrip Code: Equity - 500257**

**Subject: Disclosure pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')**

*Dear Sir/Madam,*

We would like to notify that the U.S. FDA inspected Lupin's Pithampur Unit-2 manufacturing facility from July 08 to July 17, 2025. The inspection closed with the issuance of a Form-483 with four observations.

We are addressing these observations comprehensively and will respond to the U.S. FDA within the stipulated timeframe. We uphold quality and compliance with utmost importance and are committed to be compliant with CGMP quality standards across all our facilities.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations.

Thanking you,

**For LUPIN LIMITED**

**AMIT KUMAR GUPTA  
COMPANY SECRETARY & COMPLIANCE OFFICER  
(ACS -15754)**

LUPIN LIMITED

Registered Office: 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

[www.lupin.com](http://www.lupin.com)